Erirab DSR 30mg/20mg Capsule is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, indicated for the management of gastroesophageal reflux disease (GERD), acid peptic disorders, and related gastrointestinal conditions. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the tone of the lower esophageal sphincter and accelerating gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in gastric parietal cells, promoting mucosal healing and symptom relief in acid-related disorders. The combination therapy offers synergistic benefits by addressing both acid suppression and motility enhancement, improving patient outcomes in conditions like GERD, erosive esophagitis, and functional dyspepsia. Erirab DSR is typically administered orally once daily before meals, with dosage adjustments based on clinical response and tolerability. Caution is advised in patients with hepatic impairment, and it is contraindicated in individuals with known hypersensitivity to either component. Common adverse effects may include headache, dry mouth, abdominal discomfort, and, rarely, extrapyramidal symptoms. Consultation with a healthcare professional is essential before initiating therapy to ensure appropriate use and monitoring.